scholarly journals Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes

2017 ◽  
Vol 19 (S3) ◽  
pp. S-25-S-37 ◽  
Author(s):  
David Rodbard
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Outcomes

scholarly journals Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

10.2196/21778 ◽  
2020 ◽  
Vol 22 (8) ◽  
pp. e21778 ◽  
Author(s):  
Amit R Majithia ◽  
Coco M Kusiak ◽  
Amy Armento Lee ◽  
Francis R Colangelo ◽  
Robert J Romanelli ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Prospective Trial ◽  
Glucose Monitoring ◽  
Mobile App ◽  
Diabetes Clinic ◽  
Percent Time ◽  
Glycemic Outcomes

Background The Onduo virtual diabetes clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote personalized lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices for intermittent use. Objective This prospective single-arm study evaluated glycemic outcomes associated with participation in the Onduo VDC for 4 months. Methods Adults aged ≥18 years with T2D and a baseline glycated hemoglobin (HbA1c) of ≥8% to ≤12% were enrolled from 2 primary care centers from February 2019 to October 2019. Participants were asked to engage at ≥1 time per week with their care team and to participate in a telemedicine consultation with a clinic endocrinologist for diabetes medication review. Participants were asked to use a RT-CGM device and wear six 10-day sensors (total 60 days of sensor wear) intermittently over the course of 4 months. The primary outcome was change in HbA1c at 4 months from baseline. Other endpoints included change in weight and in RT-CGM glycemic metrics, including percent time <70, 70-180, 181-250, and >250 mg/dL. Changes in blood pressure and serum lipids at 4 months were also evaluated. Results Participants (n=55) were 57.3 (SD 11.6) years of age, body mass index 33.7 (SD 7.2), and 40% (22/55) female. HbA1c decreased significantly by 1.6% (SD 1%; P<.001). When stratified by baseline HbA1c of 8.0% to 9.0% (n=36) and >9.0% (n=19), HbA1c decreased by 1.2% (SD 0.6%; P<.001) and 2.4% (SD 1.3%; P<.001), respectively. Continuous glucose monitoring–measured (n=43) percent time in range (TIR) 70-180 mg/dL increased by 10.2% (SD 20.5%; P=.002), from 65.4% (SD 23.2%) to 75.5% (SD 22.7%), which was equivalent to a mean increase of 2.4 hours TIR per day. Percent time 181-250 mg/dL and >250 mg/dL decreased by 7.2% (SD 15.4; P=.005) and 3.0% (SD 9.4; P=.01), respectively. There was no change in percent time <70 mg/dL. Mean weight decreased by 9.0 lb (SD 10.4; P<.001). Significant improvements were also observed in systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides (P=.04 to P=<.001). Conclusions Participants in the Onduo VDC experienced significant improvement in HbA1c, increased TIR, decreased time in hyperglycemia, and no increase in hypoglycemia at 4 months. Improvements in other metabolic health parameters including weight and blood pressure were also observed. In conclusion, the Onduo VDC has potential to support people with T2D and their clinicians between office visits by increasing access to specialty care and advanced diabetes technology including RT-CGM. Trial Registration ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381

scholarly journals Inpatient Continuous Glucose Monitoring and Glycemic Outcomes

2017 ◽  
Vol 11 (5) ◽  
pp. 1028-1035 ◽  
Author(s):  
David L. Levitt ◽  
Kristi D. Silver ◽  
Elias K. Spanakis
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Outcomes

scholarly journals Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study

Diabetes Care ◽  
2019 ◽  
Vol 43 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Jan Šoupal ◽  
Lenka Petruželková ◽  
George Grunberger ◽  
Aneta Hásková ◽  
Milan Flekač ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Insulin Delivery ◽  
Delivery Method ◽  
Glycemic Outcomes

scholarly journals Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial (Preprint)

2020 ◽  
Author(s):  
Amit R Majithia ◽  
Coco M Kusiak ◽  
Amy Armento Lee ◽  
Francis R Colangelo ◽  
Robert J Romanelli ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Prospective Trial ◽  
Glucose Monitoring ◽  
Mobile App ◽  
Diabetes Clinic ◽  
Percent Time ◽  
Glycemic Outcomes

BACKGROUND The Onduo virtual diabetes clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote personalized lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices for intermittent use. OBJECTIVE This prospective single-arm study evaluated glycemic outcomes associated with participation in the Onduo VDC for 4 months. METHODS Adults aged ≥18 years with T2D and a baseline glycated hemoglobin (HbA1c) of ≥8% to ≤12% were enrolled from 2 primary care centers from February 2019 to October 2019. Participants were asked to engage at ≥1 time per week with their care team and to participate in a telemedicine consultation with a clinic endocrinologist for diabetes medication review. Participants were asked to use a RT-CGM device and wear six 10-day sensors (total 60 days of sensor wear) intermittently over the course of 4 months. The primary outcome was change in HbA1c at 4 months from baseline. Other endpoints included change in weight and in RT-CGM glycemic metrics, including percent time &lt;70, 70-180, 181-250, and &gt;250 mg/dL. Changes in blood pressure and serum lipids at 4 months were also evaluated. RESULTS Participants (n=55) were 57.3 (SD 11.6) years of age, body mass index 33.7 (SD 7.2), and 40% (22/55) female. HbA1c decreased significantly by 1.6% (SD 1%; <i>P</i>&lt;.001). When stratified by baseline HbA1c of 8.0% to 9.0% (n=36) and &gt;9.0% (n=19), HbA1c decreased by 1.2% (SD 0.6%; <i>P</i>&lt;.001) and 2.4% (SD 1.3%; <i>P</i>&lt;.001), respectively. Continuous glucose monitoring–measured (n=43) percent time in range (TIR) 70-180 mg/dL increased by 10.2% (SD 20.5%; <i>P</i>=.002), from 65.4% (SD 23.2%) to 75.5% (SD 22.7%), which was equivalent to a mean increase of 2.4 hours TIR per day. Percent time 181-250 mg/dL and &gt;250 mg/dL decreased by 7.2% (SD 15.4; <i>P</i>=.005) and 3.0% (SD 9.4; <i>P</i>=.01), respectively. There was no change in percent time &lt;70 mg/dL. Mean weight decreased by 9.0 lb (SD 10.4; <i>P</i>&lt;.001). Significant improvements were also observed in systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides (<i>P</i>=.04 to P=&lt;.001). CONCLUSIONS Participants in the Onduo VDC experienced significant improvement in HbA1c, increased TIR, decreased time in hyperglycemia, and no increase in hypoglycemia at 4 months. Improvements in other metabolic health parameters including weight and blood pressure were also observed. In conclusion, the Onduo VDC has potential to support people with T2D and their clinicians between office visits by increasing access to specialty care and advanced diabetes technology including RT-CGM. CLINICALTRIAL ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381

scholarly journals Continuous Glucose Monitoring Improves Glycemic Outcomes in Children With Type 1 Diabetes: Real-world Data From a Population-Based Clinic

Diabetes Care ◽  
2021 ◽  
pp. dc210304
Author(s):  
Elaine E. Sanderson ◽  
Mary B. Abraham ◽  
Grant J. Smith ◽  
Jenny A. Mountain ◽  
Timothy W. Jones ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Real World ◽  
Glucose Monitoring ◽  
Population Based ◽  
Real World Data ◽  
World Data ◽  
Glycemic Outcomes
Sign in / Sign up

Export Citation Format

Share Document